Opko Health, Inc.
4400 Biscayne Boulevard
Miami
Florida
33137
United States
Tel: 305-575-4100
Website: http://www.opko.com/
Email: contact@opko.com
321 articles about Opko Health, Inc.
-
Opko Health, Inc. Receives FDA 510(k) Clearance for Spectral OCT SLO Combination Imaging System
1/23/2009
-
Opko Health, Inc. Initiates Clinical Trial of the Aquashunt(TM) to Treat Glaucoma
1/22/2009
-
Opko Health, Inc. Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD
12/4/2008
-
Opko Health, Inc. Acquires Worldwide Ophthalmic Rights to Teva Pharmaceutical Industries Limited's Budesonide for Inflammatory and Allergic Ocular Conditions
10/3/2008
-
Opko Health, Inc. Set to Join Russell 3000 Index
6/17/2008
-
Opko Health, Inc. Acquires Rights to Novel Phase II Agent to Treat Viral Conjunctivitis
6/12/2008
-
Newly Published Study Shows Opko Health, Inc.'s siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
6/3/2008
-
Opko Health, Inc. Acquires Company Developing Novel Glaucoma Therapy
5/7/2008
-
Opko Health, Inc. Announces Issuance of U.S. Patent
3/18/2008
-
Opko Health, Inc. and Pathogenics Inc. Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
2/25/2008
-
Opko Health, Inc. Appoints Industry Veteran Dr. Naveed Shams as Chief Medical Officer
1/14/2008
-
Opko Health, Inc.'s Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials
12/6/2007
-
The Frost Group Invests $20 Million in Opko Health, Inc.
12/5/2007
-
Opko Health, Inc. Completes Acquisition of Ophthalmic Technologies, Inc.
11/29/2007
-
Opko Health, Inc. Acquires Rights to Innovative Ocular Product to Prevent Serious Eye Infections
10/30/2007
-
Opko Health, Inc. Acquires Rights to Clinical Stage Compound for Dry Eye
10/11/2007
-
Opko Health, Inc. to Present at UBS Warburg 2007 Global Life Sciences Conference
9/18/2007
-
Opko Health, Inc. Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
8/30/2007
-
Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost
7/12/2007
-
Opko Health, Inc. Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD
7/11/2007